Table 1.
Basic characteristics of included studies.
| First Author | Year | Journal | Country | Type of Study | Type of Cancer | Patients (ATB+/ATB-) | mPFS,ABX+ vs ABX- (months) | mOS,ABX+ vs ABX-(months) | HR for PFS [95% CI] | p-Value for PFS | HR for OS [95% CI] | p-Value for OS | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Umang Swami (11) | 2020 | Antibiotics | USA | Retrospective | Melanoma | 30/169 | NA | NA | 1.28 [0.80,2.04] | 0.30 | 1.73 [1.00,2.99] | 0.05 | 7 |
| Cortellini (12) | 2021 | Annals of oncololgy | UK | Retrospective | NSCLC | 47/302 | 5.6 vs 6.3 | 11.2 vs 16.6 | 1.25 [0.84,1.84] | 0.26 | 1.63 [0.99,2.68] | 0.05 | 7 |
| KAZUYUKI HAMADA (13) | 2021 | Anticancer Research | Japan | Retrospective | NSCLC | 18/69 | 6.4 vs 19.9 | 20.6 vs 72.8 | 3.16 [1.55,6.25] | 0.002 | 1.99 [0.91,4.09] | 0.082 | 7 |
| KOSUKE UEDA (14) | 2019 | Anticancer Research | Japan | Retrospective | RCC | 5/31 | 2.8 vs 18.4 | NA | 6.52 [1.86,21.42] | 0.0004 | NA | NA | 7 |
| Anne Schett (15) | 2019 | Cancer Chemotherapy and Pharmacology | Switzerland | Retrospective | NSCLC | 33/218 | 1.4 vs 5.5 | 1.8 vs 15.4 | 1.27 [0.94,1.71] | 0.12 | 1.74 [1.24,2.44] | 0.001 | 7 |
| Lalani-1 (16) | 2019 | European Urology Oncology | Canada | Retrospective | RCC | 31/146 | NA | NA | 1.96 [1.20,3.20] | 0.007 | 1.44 [0.75,2.77] | 0.27 | 7 |
| Lalani-2 (16) | 2019 | European Urology Oncology | Canada | Retrospective | RCC | 709/3435 | NA | NA | 1.16 [1.04,1.30] | 0.008 | 1.25 [1.10,1.41] | 0.001 | |
| Chirayu Mohindroo (17) | 2020 | Cancer Medicine | USA | Retrospective | PDAC | 209/580 | 4.4 vs 2.0 | 13.3 vs 9.0 | 2.08 [1.44,3.01] | 0.0001 | 2.08 [1.44,3.01] | 0.0001 | 7 |
| Arielle Elkrief (18) | 2019 | OncoImmunology | Canada | Retrospective | Melanoma | 10/74 | 2.4 vs 7.3 | 10.7 vs 18.3 | 3.57 [1.36,9.40] | 0.01 | 1.92 [0.76,4.87] | 0.17 | 7 |
| L. Derosa-1 (19) | 2018 | Annals of oncololgy | France | Retrospective | NSCLC | 48/239 | 1.9 vs 3.8 | 7.9 vs 24.6 | 1.5 [1.0,2.2] | 0.03 | 4.4 [2.6,7.7] | 0.01 | 7 |
| L. Derosa-2 (19) | 2018 | Annals of oncololgy | France | Retrospective | RCC | 16/121 | 1.9 vs 7.4 | 17.3 vs 30.6 | 3.1 [1.4,6.9] | 0.01 | 3.5 [1.1,10.8] | 0.03 | |
| Laura M. Chambers (20) | 2021 | Gynecologic Oncology | USA | Retrospective | GC | 58/101 | 7.3 vs 6.8 | 11.6 vs 19.5 | 0.96 [0.59,1.54] | 0.85 | 1.20 [0.70,2.09] | 0.51 | 7 |
| Nadina Tinsley (21) | 2020 | The Oncologist | UK | Retrospective | NSCLC, others | 92/291 | 3.1 vs 6.3 | 10.4 vs 21.7 | 1.401 [1.028,1.920] | 0.033 | 1.4723 [1.038,2.107] | 0.033 | 7 |
| Hyunho Kim (22) | 2019 | BMC Cancer | Korea | Retrospective | NSCLC, others | 108/234 | 2.0 vs 4.0 | 5.0 vs 17.0 | 1.715 [1.264,2.326] | 0.001 | 1.785 [1.265,2.519] | 0.001 | 7 |
NSCLC, Non-small cell lung cancer; RCC, Renal cell carcinoma; PDAC, Pancreatic ductal adenocarcinoma; GC, Gynecological cancer; PFS, Progression free survival; OS,Overall survival; ABX, Antibiotics; ABX+, Antibiotics exposure; ABX-, No antibiotics exposure; HR, Hazard ratio; NA, Not available.